Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study

Yoshikazu Takaesu¹, Koichiro Watanabe¹, Shusuke Numata², Masaaki Iwata³, Noriko Kudo⁴, Satoru Oishi⁵, Takeya Takizawa⁵, Kiyotaka Nemoto⁶, Yuka Yasuda^{4

7}, Hiromi Tagata⁸, Takashi Tsuboi¹, Naohisa Tsujino⁹, Naoki Hashimoto¹⁰, Yuki Matsui^{4

11}, Hikaru Hori¹², Hidenaga Yamamori^{4

13}, Nobuhiro Sugiyama^{14

15}, Taro Suwa¹⁶, Taishiro Kishimoto¹⁷, Akitoyo Hishimoto¹⁸, Masahide Usami¹⁹, Ryuji Furihata²⁰, Kunihiro Iwamoto²¹, Hiroshige Fujishiro^{21

22}, Toshinori Nakamura¹⁵, Kentaro Mizuno²³, Takahiko Inagaki^{24

25}, Eiichi Katsumoto²⁶, Hiroaki Tomita²⁷, Kazutaka Ohi²⁸, Hiroyuki Muraoka²⁹, Kiyokazu Atake¹², Hitoshi Iida³⁰, Tatsuya Nagasawa²⁸, Junichi Fujita³¹, Satoshi Yamamura³², Toshiaki Onitsuka³³, Atsunobu Murata³⁴, Yoichiro Takayanagi³⁵, Hokuto Noda³⁶, Yukiko Matsumura³⁷, Kenji Takezawa³⁸, Jun-Ichi Iga³⁹, Kayo Ichihashi⁴⁰, Kazuyoshi Ogasawara^{21

41}, Hisashi Yamada^{4

42}, Ken Inada²⁹, Ryota Hashimoto^{4

43}

Affiliations

¹ Department of Neuropsychiatry, School of Medicine, Kyorin University, Tokyo, Japan.
² Department of Psychiatry, Institute of Biomedical Science, Tokushima University Graduate School, Tokushima, Japan.
³ Division of Neuropsychiatry, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan.
⁴ Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
⁵ Department of Psychiatry, Kitasato University School of Medicine, Kanagawa, Japan.
⁶ Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
⁷ Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan.
⁸ Department of Neuropsychiatry, Toho University School of Medicine, Tokyo, Japan.
⁹ Department of Psychiatry, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.
¹⁰ Department of Psychiatry, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
¹¹ Department of Psychiatry, Jindai Hospital, Aichi, Japan.
¹² Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
¹³ Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.
¹⁴ Department of Applied Occupational Therapy, Shinshu University School of Health Sciences, Nagano, Japan.
¹⁵ Department of Psychiatry, Shinshu University School of Medicine, Nagano, Japan.
¹⁶ Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁷ Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan.
¹⁸ Department of Psychiatry, Kobe University Graduate School of Medicine, Hyogo, Japan.
¹⁹ Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
²⁰ Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan.
²¹ Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
²² Department of Psychiatry, Kawasaki Memorial Hospital, Kanagawa, Japan.
²³ Wakakusa Hospital, Miyazaki, Japan.
²⁴ Biwako Hospital, Shiga, Japan.
²⁵ Department of Psychiatry, Shiga University of Medical Science, Shiga, Japan.
²⁶ Katsumoto Mental Clinic, Osaka, Japan.
²⁷ Department of Psychiatry, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
²⁸ Department of Neuropsychiatry, Kanazawa Medical University, Ishikawa, Japan.
²⁹ Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
³⁰ Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
³¹ Department of Child Psychiatry, Yokohama City University Hospital, Kanagawa, Japan.
³² Suzuka Kosei Hospital, Mie, Japan.
³³ Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
³⁴ Kyowa Hospital, Akita, Japan.
³⁵ Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
³⁶ Yamanashi Prefectural Kita Hospital, Yamanashi, Japan.
³⁷ Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
³⁸ Medical Corporation Matsuzaki Hospital, Toyohashi Mental Care Center, Aichi, Japan.
³⁹ Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, Japan.
⁴⁰ Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan.
⁴¹ Medical Research and Clinical Ethics Promotion Office, Nagoya University Hospital, Aichi, Japan.
⁴² Department of Neuropsychiatry, Hyogo College of Medicine, Hyogo, Japan.
⁴³ Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

PMID: 31437336
PMCID: PMC6852015
DOI: 10.1111/pcn.12911

Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study

Yoshikazu Takaesu et al. Psychiatry Clin Neurosci. 2019 Oct.

. 2019 Oct;73(10):642-648.

doi: 10.1111/pcn.12911. Epub 2019 Aug 22.

Authors

Affiliations

¹ Department of Neuropsychiatry, School of Medicine, Kyorin University, Tokyo, Japan.
² Department of Psychiatry, Institute of Biomedical Science, Tokushima University Graduate School, Tokushima, Japan.
³ Division of Neuropsychiatry, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan.
⁴ Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
⁵ Department of Psychiatry, Kitasato University School of Medicine, Kanagawa, Japan.
⁶ Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
⁷ Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan.
⁸ Department of Neuropsychiatry, Toho University School of Medicine, Tokyo, Japan.
⁹ Department of Psychiatry, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.
¹⁰ Department of Psychiatry, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
¹¹ Department of Psychiatry, Jindai Hospital, Aichi, Japan.
¹² Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
¹³ Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.
¹⁴ Department of Applied Occupational Therapy, Shinshu University School of Health Sciences, Nagano, Japan.
¹⁵ Department of Psychiatry, Shinshu University School of Medicine, Nagano, Japan.
¹⁶ Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁷ Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan.
¹⁸ Department of Psychiatry, Kobe University Graduate School of Medicine, Hyogo, Japan.
¹⁹ Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
²⁰ Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan.
²¹ Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
²² Department of Psychiatry, Kawasaki Memorial Hospital, Kanagawa, Japan.
²³ Wakakusa Hospital, Miyazaki, Japan.
²⁴ Biwako Hospital, Shiga, Japan.
²⁵ Department of Psychiatry, Shiga University of Medical Science, Shiga, Japan.
²⁶ Katsumoto Mental Clinic, Osaka, Japan.
²⁷ Department of Psychiatry, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
²⁸ Department of Neuropsychiatry, Kanazawa Medical University, Ishikawa, Japan.
²⁹ Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
³⁰ Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
³¹ Department of Child Psychiatry, Yokohama City University Hospital, Kanagawa, Japan.
³² Suzuka Kosei Hospital, Mie, Japan.
³³ Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
³⁴ Kyowa Hospital, Akita, Japan.
³⁵ Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
³⁶ Yamanashi Prefectural Kita Hospital, Yamanashi, Japan.
³⁷ Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
³⁸ Medical Corporation Matsuzaki Hospital, Toyohashi Mental Care Center, Aichi, Japan.
³⁹ Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, Japan.
⁴⁰ Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan.
⁴¹ Medical Research and Clinical Ethics Promotion Office, Nagoya University Hospital, Aichi, Japan.
⁴² Department of Neuropsychiatry, Hyogo College of Medicine, Hyogo, Japan.
⁴³ Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

PMID: 31437336
PMCID: PMC6852015
DOI: 10.1111/pcn.12911

Abstract

Aim: Although treatment guidelines for pharmacological therapy for schizophrenia and major depressive disorder have been issued by the Japanese Societies of Neuropsychopharmacology and Mood Disorders, these guidelines have not been well applied by psychiatrists throughout the nation. To address this issue, we developed the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' integrated education programs for psychiatrists to disseminate the clinical guidelines. Additionally, we conducted a systematic efficacy evaluation of the programs.

Methods: Four hundred thirteen out of 461 psychiatrists attended two 1-day educational programs based on the treatment guidelines for schizophrenia and major depressive disorder from October 2016 to March 2018. We measured the participants' clinical knowledge of the treatment guidelines using self-completed questionnaires administered before and after the program to assess the effectiveness of the programs for improving knowledge. We also examined the relation between the participants' demographics and their clinical knowledge scores.

Results: The clinical knowledge scores for both guidelines were significantly improved after the program. There was no correlation between clinical knowledge and participant demographics for the program on schizophrenia; however, a weak positive correlation was found between clinical knowledge and the years of professional experience for the program on major depressive disorder.

Conclusion: Our results provide evidence that educational programs on the clinical practices recommended in guidelines for schizophrenia and major depressive disorder might effectively improve participants' clinical knowledge of the guidelines. These data are encouraging to facilitate the standardization of clinical practices for psychiatric disorders.

Keywords: EGUIDE project; educational program; major depressive disorder; schizophrenia; treatment guideline.

PubMed Disclaimer

Figures

**Figure 1**
Distribution of clinical knowledge scores at () baseline and () post‐program. (a) ‘Guideline for Pharmacological Therapy for Schizophrenia.’ (b) ‘Treatment Guideline II: Major Depressive Disorder.’

formula image — **Figure 1**
Distribution of clinical knowledge scores at () baseline and () post‐program. (a) ‘Guideline for Pharmacological Therapy for Schizophrenia.’ (b) ‘Treatment Guideline II: Major Depressive Disorder.’

See this image and copyright information in PMC

References

1. American Psychiatric Association Work Group on Psychiatric Evaluation . The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults, 3rd edn. American Psychiatric Association, Arlington, VA, 2016.
1. Keating D, McWilliams S, Schneider I et al Pharmacological guidelines for schizophrenia: A systematic review and comparison of recommendations for the first episode. BMJ Open 2017; 7: e013881. - PMC - PubMed
1. Bauer M, Severus E, Moller HJ, Young AH. WFSBP Task Force on Unipolar Depressive DisordersPharmacological treatment of unipolar depressive disorders: Summary of WFSBP guidelines. Int. J. Psychiatry Clin. Pract. 2017; 21: 166–176. - PubMed
1. Hasan A, Falkai P, Wobrock T et al World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia ‐ A short version for primary care. Int. J. Psychiatry Clin. Pract. 2017; 21: 82–90. - PubMed
1. Kennedy SH, Lam RW, McIntyre RS et al Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Can. J. Psychiatry 2016; 61: 540–560. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study

Affiliations

Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical